William Bensinger

Medicine · Health Sciences

65h-index20.8kcitations328works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(166), Hematopoietic Stem Cell Transplantation(96), Protein Degradation and Inhibitors(69), Peptidase Inhibition and Analysis(35), Chronic Lymphocytic Leukemia Research(34)

Publications321 total

P-355 Melphalan vs Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) As Preparative Regimen for Newly Diagnosed Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Clinical Lymphoma Myeloma & Leukemia·2024
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2024· 2 citedOpen Access
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
Clinical Lymphoma Myeloma & Leukemia·2023· 13 citedOpen Access
Supplementary Figures 1 and 2 and Supplementary Methods from A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
2023Open Access
Data from A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
2023Open Access
Data from A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
2023Open Access
Supplementary Figures 1 and 2 and Supplementary Methods from A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
2023Open Access
Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma
Blood·2022· 4 cited
Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
eJHaem·2022· 16 citedOpen Access
MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2022· 5 cited
Poster: MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2022
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma
Clinical Lymphoma Myeloma & Leukemia·2022· 1 cited
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study
Leukemia & lymphoma/Leukemia and lymphoma·2022· 17 citedOpen Access
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
The Lancet Haematology·2022· 44 cited
A Prospective Randomized Trial Comparing Conditioning with Either BEAM or High-Dose Melphalan Prior to Autologous Transplantation for Patients with Multiple Myeloma: An Evaluation of Interim Safety in Early Recovery Phase
Transplantation and Cellular Therapy·2022
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
British Journal of Cancer·2021· 42 citedOpen Access
Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2021· 34 cited
Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma
Blood·2021
Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)
Blood·2021· 2 cited
An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma
Blood·2021· 5 cited
page 1 of 17Next →

Frequent Co-authors

Frederick R. Appelbaum(14), Rainer Storb(12), Reginald A. Clift(9), David G. Maloney(8), Thomas R. Chauncey(8), Mary E.D. Flowers(7), Jesús F. San Miguel(7), Scott D. Rowley(7), Paul J. Martin(6), Rubén Niesvizky(6), Sergio Giralt(6), Kenneth C. Anderson(6), John A. Hansen(5), Robert P. Witherspoon(5), Brenda M. Sandmaier(5), David S. Siegel(5), Andrzej Jakubowiak(5), Heinz Ludwig(5), Philippe Moreau(5), Barry E. Storer(5)